Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa
Stopped early · Phase 3
Conditions studied: Pneumonia
In brief
This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability, and pharmacokinetics of intravenous murepavadin combined with of one anti-pseudononas antibiotic with that of two anti-pseudomonas antibiotics in the treatment of ventilator-associated bacterial pneumonia (VABP) in adult subjects.
Key facts
- Study ID
- NCT03409679
- Run by
- Polyphor Ltd.
- People needed
- 41
- Starts
- 2018-03-23
- Expected to finish
- 2019-07-17
- Last updated by the study team
- 2019-08-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research site — Springfield, Missouri, United States
- Research site — Greensboro, North Carolina, United States
- Research Site 1 — Belo Horizonte, Brazil
- Research Site 2 — Belo Horizonte, Brazil
- Research Site — Itaquaquecetuba, Brazil
- Research Site — Porto Alegre, Brazil
- Research Site — São José do Rio Preto, Brazil
- Research site 1 — Zagreb, Croatia
- Research site 2 — Zagreb, Croatia
- Research site — Tallinn, Estonia
- Reasearch site — Tartu, Estonia
- Reasearch site — Võru, Estonia
- Research site — Lille, France
- Reasearch site — Limoges, France
- Research site — Lyon, France
- Reasearch site — Nice, France
- Research site 1 — Paris, France
- Research site 2 — Paris, France
- Research site 3 — Paris, France
- Research site — Pierre-Bénite, France
- Research Site — Athens, Greece
- Research Site — Ioannina, Greece
- Research Site 1 — Larissa, Greece
- Research Site 2 — Larissa, Greece
- Research site — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.